CONSENSO SOBRE CONTRACEÇÃO 2020

Contraceção Hormonal e Intrauterina com Condições Médicas Especiais | DOENÇAS DO APARELHO REPRODUTOR | D5
BIBLIOGRAFIA
1. Curtis, K. M. et al. U.S. Medical Eligibility Criteria for Contraceptive Use,
2016. MMWR. Recommendations and reports: Morbidity and mortality
weekly report. Recommendations and reports / Centers for Disease Control
65, (2016).
2. WHO. Medical eligibility criteria for contraceptive use. WHO (2015).
3. Iyer, V., Farquhar, C. & Jepson, R. Oral contraceptive pills for heavy
menstrual bleeding. The Cochrane database of systematic reviews
CD000154 (2000). doi:10.1002/14651858.CD000154
4. Barrington, J. W., Arunkalaivanan, A. S. & Abdel-Fattah, M. Comparison
between the levonorgestrel intrauterine system (LNG-IUS) and thermal
balloon ablation in the treatment of menorrhagia. European journal of
obstetrics, gynecology, and reproductive biology 108, 72–4 (2003).
5. Gupta, B., Mittal, S., Misra, R., Deka, D. & Dadhwal, V. Levonorgestrel-releasing
intrauterine system vs. transcervical endometrial
resection for dysfunctional uterine bleeding. International journal of
gynaecology and obstetrics: the official organ of the International Federation
of Gynaecology and Obstetrics 95, 261–6 (2006).
6. Hurskainen, R. et al. Quality of life and cost-effectiveness of levonorgestrel-releasing
intrauterine system versus hysterectomy for treatment
of menorrhagia: a randomised trial. Lancet (London, England) 357, 273–7
(2001).
7. Lethaby, A., Hussain, M., Rishworth, J. R. & Rees, M. C. Progesterone
or progestogen-releasing intrauterine systems for heavy
menstrual bleeding. The Cochrane database of systematic reviews
CD002126 (2015). doi:10.1002/14651858.CD002126.pub3
8. Stewart, A., Cummins, C., Gold, L., Jordan, R. & Phillips, W. The effectiveness
of the levonorgestrel-releasing intrauterine system in menorrhagia:
a systematic review. BJOG: an international journal of obstetrics
and gynaecology 108, 74–86 (2001).
9. Bulun, S. E. Uterine fibroids. The New England journal of medicine 369,
1344–55 (2013).
10. Kim, J. J., Kurita, T. & Bulun, S. E. Progesterone action in endometrial
cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine
reviews 34,130–62 (2013).
11. Sociedade Portuguesa de Ginecologia. Consenso nacional sobre
hemorragias uterinas anormais. (2018).
12. Marret, H. et al. Therapeutic management of uterine fibroid tumors:
updated French guidelines. European journal of obstetrics, gynecology, and
reproductive biology 165, 156–64 (2012).
13. Grigorieva, V., Chen-Mok, M., Tarasova, M. & Mikhailov, A. Use of
a levonorgestrel-releasing intrauterine system to treat bleeding related
to uterine leiomyomas. Fertility and sterility 79, 1194–8 (2003).
14. Wildemeersch, D. & Schacht, E. The effect on menstrual blood loss
in women with uterine fibroids of a novel ‘frameless’ intrauterine levonorgestrel-releasing
drug delivery system: a pilot study. European journal
of obstetrics, gynecology, and reproductive biology 102, 74–9 (2002).
15. Mercorio, F. et al. The effect of a levonorgestrel-releasing intrauterine
device in the treatment of myoma-related menorrhagia. Contraception
67, 277–80 (2003).
16. Sociedade Portuguesa de Ginecologia. Miomas uterinos. (2017).
17. Proctor, M. L., Roberts, H. & Farquhar, C. M. Combined oral
contraceptive pill (OCP) as treatment for primary dysmenorrhoea.
The Cochrane database of systematic reviews CD002120 (2001).
doi:10.1002/14651858.CD002120
18. Hendrix, S. L. & Alexander, N. J. Primary dysmenorrhea treatment
with a desogestrel-containing low-dose oral contraceptive. Contraception
66, 393–9 (2002).
19. ACOG. ACOG Practice Bulletin No. 110: noncontraceptive uses of
hormonal contraceptives. Obstetrics and gynecology 115, 206–18 (2010).
20. Johnson, N. P., Hummelshoj, L. & World Endometriosis Society
Montpellier Consortium. Consensus on current management of endometriosis.
Human reproduction (Oxford, England) 28, 1552–68 (2013).
21. Soares, S. R., Martínez-Varea, A., Hidalgo-Mora, J. J. & Pellicer,
A. Pharmacologic therapies in endometriosis: a systematic review.
Fertility and sterility 98, 529–55 (2012).
22. Dunselman, G. A. J. et al. ESHRE guideline: management of
women with endometriosis. Human reproduction (Oxford, England) 29,
400–12 (2014).
23. Lockhat, F. B., Emembolu, J. O. & Konje, J. C. The evaluation of
the effectiveness of an intrauterine-administered progestogen (levonorgestrel)
in the symptomatic treatment of endometriosis and in
the staging of the disease. Human reproduction (Oxford, England) 19,
179–84 (2004).
24. Petta, C. A. et al. Randomized clinical trial of a levonorgestrelreleasing
intrauterine system and a depot GnRH analogue for the
treatment of chronic pelvic pain in women with endometriosis. Human
reproduction (Oxford, England) 20, 1993–8 (2005).
25. Vercellini, P. et al. A levonorgestrel-releasing intrauterine system
for the treatment of dysmenorrhea associated with endometriosis:
a pilot study. Fertility and sterility 72, 505–8 (1999).
26. Bright, P. L. et al. Hormonal contraception and area of cervical
ectopy: a longitudinal assessment. Contraception 84, 512–9 (2011).
27. La Vecchia, C. & Boccia, S. Oral contraceptives, human papillomavirus
and cervical cancer. European journal of cancer prevention: the
official journal of the European Cancer Prevention Organisation (ECP) 23,
110–2 (2014).
28. Cibula, D. et al. Hormonal contraception and risk of cancer. Human
Reproduction Update 16, 631–650 (2010).
29. Smith, J. S. et al. Cervical cancer and use of hormonal contraceptives:
a systematic review. Lancet (London, England) 361, 1159–67 (2003).
30. Moreno, V. et al. Effect of oral contraceptives on risk of cervical
cancer in women with human papillomavirus infection: the IARC multicentric
case-control study. Lancet (London, England) 359, 1085–92
(2002).
31. Cortessis, V. K. et al. Intrauterine Device Use and Cervical Cancer
Risk: A Systematic Review and Meta-analysis. Obstetrics and gynecology
130, 1226–1236 (2017).
32. Gompel, A., Ramirez, I. & Bitzer, J. Contraception in cancer survivors
– an expert review Part I. Breast and gynaecological cancers.
The European Journal of Contraception & Reproductive Health Care 24,
167–174 (2019).
33. Adewole, I. F., Oladokun, A., Fawole, A. O., Olawuyi, J. F. & Adeleye,
J. A. Fertility regulatory methods and development of complications
after evacuation of complete hydatidiform mole. Journal of obstetrics
and gynaecology: the journal of the Institute of Obstetrics and Gynaecology
20, 68–9 (2000).
34. Seckl, M. J. et al. Gestational trophoblastic disease: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Annals of
oncology: official journal of the European Society for Medical Oncology
24 Suppl 6, vi39-50 (2013).
35. World Health Organization Department of Reproductive Health
and Research, Hopkins, J., For, B. S. of P. H. C. for C. P. K. for & Health
project. Family Planning A GLOBAL HANDBOOK FOR PROVIDERS. (2018).
96